# FLT3

Source: https://onco.cc/targets/flt3/  
OnCo record `flt3` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FLT3 is a kinase mutated in about a third of acute myeloid leukaemias, where adding an inhibitor to chemotherapy improves survival.

## Summary

FLT3 is a class III receptor tyrosine kinase, and internal tandem duplications (ITD) or tyrosine kinase domain (TKD) mutations activate it in roughly 25 to 30 percent of acute myeloid leukaemias, with ITD predicting shorter survival. Adding a FLT3 inhibitor to intensive chemotherapy improves survival: midostaurin, gilteritinib and quizartinib are approved, with quizartinib and midostaurin used in the front line and gilteritinib in relapsed disease. Combinations with venetoclax and with menin inhibitors are being tested to deepen and prolong responses. Resistance through emergent TKD mutations, clonal switching and the role of FLT3 inhibitors as maintenance after transplant remain open. For a newcomer: FLT3 is the AML kinase where a targeted pill added to chemotherapy has clearly extended lives.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: driver; kinase
- Symbol: FLT3
- Class: kinase
- Biology: Class III receptor tyrosine kinase; ITD predicts shorter survival.
- Where found: Acute myeloid leukaemia

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/CD135
- Wikipedia: https://en.wikipedia.org/wiki/CD135

## Connected records

- biomarkers: [FLT3-ITD (internal tandem duplication)](https://onco.cc/biomarkers/flt3-itd/), [FLT3-TKD (D835 and I836 tyrosine kinase domain mutations)](https://onco.cc/biomarkers/flt3-tkd/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Acute myeloid leukaemia in children](https://onco.cc/cancers/aml-paediatric/), [Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)](https://onco.cc/cancers/advanced-systemic-mastocytosis/), [FLT3-mutated acute myeloid leukaemia](https://onco.cc/cancers/aml-flt3/), [Systemic mastocytosis](https://onco.cc/cancers/systemic-mastocytosis/)
- drugs: [Fedratinib](https://onco.cc/drugs/fedratinib/), [Gilteritinib](https://onco.cc/drugs/gilteritinib/), [MEN1703](https://onco.cc/drugs/men1703/), [Midostaurin](https://onco.cc/drugs/midostaurin/), [Pacritinib](https://onco.cc/drugs/pacritinib/), [Quizartinib](https://onco.cc/drugs/quizartinib/)
- companies: [Aptose Biosciences](https://onco.cc/companies/aptose/), [Arog Pharmaceuticals](https://onco.cc/companies/arog-pharmaceuticals/), [Cullinan Therapeutics](https://onco.cc/companies/cullinan-therapeutics/)
- pathways: [Acute myeloid leukaemia (KEGG map)](https://onco.cc/pathways/aml-signalling/), [Menin / KMT2A (HOXA9-MEIS1 axis)](https://onco.cc/pathways/menin-kmt2a/), [Receptor tyrosine kinase activation](https://onco.cc/pathways/rtk-activation/)
- targets: [NPM1 mutation](https://onco.cc/targets/npm1/), [Protein kinase C family (PKC)](https://onco.cc/targets/pkc/), [STAT5 (STAT5A, STAT5B)](https://onco.cc/targets/stat5/)
- terms: [ELN 2022 risk classification](https://onco.cc/terms/eln-risk/), [FLT3-ITD allelic ratio](https://onco.cc/terms/flt3-itd-allelic-ratio/)
- trials: [ADMIRAL](https://onco.cc/trials/admiral/), [QuANTUM-First](https://onco.cc/trials/quantum-first/), [RATIFY (CALGB 10603)](https://onco.cc/trials/ratify/)
- pairings: [FLT3 inhibitor + intensive chemotherapy](https://onco.cc/pairings/flt3i-plus-7-3/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- people: [Alexander E. Perl](https://onco.cc/people/alexander-perl/), [Eunice S. Wang](https://onco.cc/people/eunice-wang/), [Hartmut Döhner](https://onco.cc/people/hartmut-dohner/), [Richard M. Stone](https://onco.cc/people/richard-stone/)
- key papers: [ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia](https://onco.cc/key-papers/paper-admiral-gilteritinib-flt3-nejm-2019/), [QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML](https://onco.cc/key-papers/paper-quantum-first-quizartinib-lancet-2023/)
- roadmaps: [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/flt3.json